These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 831730)

  • 1. Reversal of toxicity and antitumor activity of N-(phosphonacetyl)-L-aspartate by uridine or carbamyl-DL-asparate in vivo.
    Johnson RK
    Biochem Pharmacol; 1977 Jan; 26(1):81-4. PubMed ID: 831730
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
    Moyer JD; Handschumacher RE
    Cancer Res; 1979 Aug; 39(8):3089-94. PubMed ID: 455293
    [No Abstract]   [Full Text] [Related]  

  • 3. N-(phosphonacetyl)-L-aspartate, a potent transition state analog inhibitor of aspartate transcarbamylase, blocks proliferation of mammalian cells in culture.
    Swyryd EA; Seaver SS; Stark GR
    J Biol Chem; 1974 Nov; 249(21):6945-50. PubMed ID: 4371054
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
    Johnson RK; Swyryd EA; Stark GR
    Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
    [No Abstract]   [Full Text] [Related]  

  • 5. Antitumor activity of N-(phosphonacetyl)-L-aspartic acid, a transition-state inhibitor of aspartate transcarbamylase.
    Johnson RK; Inouye T; Goldin A; Stark GR
    Cancer Res; 1976 Aug; 36(8):2720-5. PubMed ID: 1064466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of synergy between N-phosphonacetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line.
    Chan TC; Howell SB
    Cancer Res; 1985 Aug; 45(8):3598-604. PubMed ID: 4016741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematologic and histopathologic evaluation of N-(phosphonacetyl)-L-aspartate (PALA) in mice.
    Harrison SD; Giles HD; Denine EP
    Cancer Chemother Pharmacol; 1979; 2(3):183-7. PubMed ID: 455573
    [No Abstract]   [Full Text] [Related]  

  • 8. Selective inhibition of pyrimidine biosynthesis and effect on proliferative growth of colonic cancer cells.
    Tsuboi KK; Edmunds NH; Kwong LK
    Cancer Res; 1977 Sep; 37(9):3080-7. PubMed ID: 884665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in human mammary carcinoma.
    Ardalan B; Glazer RI; Kensler TW; Jayaram HN; Van Pham T; Macdonald JS; Cooney DA
    Biochem Pharmacol; 1981 Aug; 30(15):2045-9. PubMed ID: 7295324
    [No Abstract]   [Full Text] [Related]  

  • 10. m-AMSA and PALA: two new agents in cancer chemotherapy.
    Rozencweig M; Von Hoff DD; Cysyk RL; Muggia FM
    Cancer Chemother Pharmacol; 1979; 3(3):135-41. PubMed ID: 393427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma.
    Kensler TW; Reck LJ; Cooney DA
    Cancer Res; 1981 Mar; 41(3):905-9. PubMed ID: 7459876
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice.
    Karle JM; Anderson LW; Dietrick DD; Cysyk RL
    Cancer Res; 1981 Dec; 41(12 Pt 1):4952-5. PubMed ID: 6171344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).
    Valdivieso M; Moore EC; Burgess AM; Marti JR; Russ J; Plunkett W; Loo TL; Bodey GP; Freireich EJ
    Cancer Treat Rep; 1980; 64(2-3):285-92. PubMed ID: 7407763
    [No Abstract]   [Full Text] [Related]  

  • 14. Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid.
    Kensler TW; Mutter G; Hankerson JG; Reck LJ; Harley C; Han N; Ardalan B; Cysyk RL; Johnson RK; Jayaram HN; Cooney DA
    Cancer Res; 1981 Mar; 41(3):894-904. PubMed ID: 7459875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
    Karle JM; Anderson LW; Erlichman C; Cysyk RL
    Cancer Res; 1980 Aug; 40(8 Pt 1):2938-40. PubMed ID: 7388844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.
    Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Young CW
    Cancer Res; 1983 Oct; 43(10):4653-61. PubMed ID: 6603903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
    Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B
    Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772
    [No Abstract]   [Full Text] [Related]  

  • 18. Phosphonacetyl-L-aspartate: an aspartate transcarbamylase inhibitor causing larval death and rudimentary wing phenocopies in Drosophila melanogaster.
    Holaday BJ; Fristrom JW
    Experientia; 1977 Apr; 33(4):428-30. PubMed ID: 405235
    [No Abstract]   [Full Text] [Related]  

  • 19. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
    Friedman J; Moore EC; Hall SW; Loo TL
    Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate.
    Moore EC; Friedman J; Valdivieso M; Plunkett W; Marti JR; Russ J; Loo TL
    Biochem Pharmacol; 1982 Oct; 31(20):3317-21. PubMed ID: 7150358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.